Using recombinant adenoviral vectors, we expressed and characterized the large, middle, and major envelope proteins of hepatitis B virus (HBV). Cells infected with the recombinant adenovirus which contained the large envelope gene (HS1.HP) expressed predominantly large envelope and small but detectable quantities of middle (4%) and major (6%) envelope proteins in the cell lysate. No HBV envelope proteins were detected in the culture medium from HS1.HP-infected cells. Cells infected with a recombinant adenovirus which contained the middle envelope gene (HS2.HP) expressed and secreted the middle and major envelope proteins in a molar ratio of 3:1. Cells infected with the recombinant adenovirus which contained the major envelope gene (HS.HP) expressed and secreted major envelope proteins. The HBV envelope proteins secreted by cells infected with either HS2.HP or HS.HP were assembled in 22-nm particles, as shown by velocity sedimentation rate determination, buoyant densities, and electron microscopy. Cells coinfected with a recombinant adenovirus which contained the large envelope gene and with either HS2.HP or HS.HP expressed similar quantities of the large, middle, and major envelope proteins in the cell lysates. Secretion of the major and middle envelope proteins was inhibited more than 95% by the presence of the large envelope proteins. These results suggest that differential biosynthesis, transport, and processing of the envelope proteins occur during HBV infection, allowing efficient assembly and secretion of virions and hepatitis B surface antigen particles.
Hepatitis B virus (HBV) infection is a serious global health problem. The 200 million chronic HBV carriers in the world
have an increased risk of developing chronic hepatitis, cirrhosis, and hepatocellular carcinoma (2) . The development of a safe, effective, and inexpensive vaccine would help stem the vertical and horizontal transmission of HBV. Previous vaccine production has involved the isolation of the noninfectious particles from chronic HBV carriers and subsequent inactivation of the contaminating virions (52) . Noninfectious hepatitis B particles in both filamentous and spherical forms are readily secreted into the blood in great excess of virions during both acute infection and the chronic carrier state. These 22-nm particles, classically called surface antigen particles, consist predominantly of the major envelope protein p24 and its glycosylated form, gp27 (17, 56) . (The major envelope proteins have also been called HBV surface antigens and the major surface antigen proteins.) Two additional sets of related envelope proteins recently have been shown to be constituents of the surface antigen particles and more predominantly the envelope of the virions (17, 53) . The middle envelope proteins, gp33 and gp36, are glycosylated at one and two sites, respectively (17, 53) . The large envelope proteins are either not glycosylated (p39) or glycosylated at one site (gp42) (17) . (The middle and large envelope proteins have also been called the middle and large surface antigens.) Recently, vaccines which contain solely the major envelope proteins have been developed (4, 46) . However, the induction of a good antibody response to the major envelope determinants is dependent on the haplotype of the major histocompatibility complex in mice (29, 31) and probably also in humans (10, 58) . Recent studies have shown that vaccines which contain the large or middle envelope determinants are more highly immunogenic than vaccines which contain solely major envelope polypeptides (23) . Thus, the production of the major, middle, and large * Corresponding author.
envelope proteins in an immunogenic configuration by an inexpensive expression system such as a viral vector (7, 8, 11, 29b, 30, 36, 49) would be a good approach toward developing an optimal vaccine. Although many laboratories have shown that the major envelope proteins by themselves can assemble into immunogenic particles (11, 36, 39, 40, 49) , the interactions of the middle and large envelope proteins in the assembly process remain unclear.
The three sets of envelope proteins are encoded within one open reading frame (ORF) of the HBV genome which uses three translation start sites. The first, second, and third ATGs are used to initiate the translation of the large, middle, and major envelope proteins, respectively, and synthesis of the proteins proceeds to the end of the ORF (17, 56) . For historical reasons, the DNA sequence between the first and second ATG is referred to as pre-Sl, between the second and third ATG as pre-S2, and between the third and the end of the ORF as S (56) . The pre-Sl region codes for 108 to 119 amino acids (depending on the subtype), the pre-S2 region for 55 amino acids, and the S region for 226 amino acids (56) .
We have previously shown that adenovirus type S could be engineered to express HBV major envelope polypeptides which were readily secreted into the medium and appeared to be assembled into particlelike structures, based on their density and sedimentation rate (11 (19) was used to infect KB suspension cells at a multiplicity of infection (MOI) of 5. At 40 h after infection, the cells were harvested and the viral DNA was isolated as described previously (54) . Briefly, the cells were disrupted by freeze-thaw cycles followed by ultrasonic treatment. After Freon extraction, the adenoviral capsids were purified by two successive bandings in isopycnic CsCl gradients. After extensive dialysis, the capsids were treated with pronase (2 mg/ml; Calbiochem, LaJolla, Calif.) in 10 mM Tris hydrochloride (pH 8.0)-10 mM EDTA-0.6% sodium dodecyl sulfate (SDS) at 37°C. DNA was obtained after phenol extraction (three times), chloroform-isopropanol (24:1) extraction (three times), and ethanol precipitation. Viral DNA was used for transfection. Construction of recombinant adenoviruses. Plasmids were constructed to insert the large, middle, and major envelope genes into the El region of the adenovirus (Fig. 1) . Briefly, the HBV sequences which contained the coding sequence for the appropriate envelope gene and the HBV polyadenylation signal (6, 44, 45, 47) were inserted downstream of the major late promoter (MLP) and tripartite leader (TPL) of the previously described plasmid pMPCV2 (25) (Fig. 1B) . The plasmid, pBRadw2, contained a head-to-tail dimer of an adw2 isolate of HBV. The HBV major, middle, and large envelope sequences were excised from the pBRadw2 plasmid by digestion with FnuDII (nucleotide [nt] 131), SauI (nt 3185), and CfoI (nt 2811), respectively. After Klenow or T4 DNA polymerase treatment, XhoI linkers were added. The fragments were digested with XhoI and HgaI (nt 1192) and isolated by electroelution. A second fragment which extended from HgaI (nt 1192) to BglII (nt 1987) was also prepared. The envelope genes were inserted downstream of the copy of the adenovirus MLP and cDNA copy of leaders 1 and 2 and 56 of 88 base pairs of leader 3 in the El region of the adenovirus type 5 plasmid pMPCV2, generously provided by J. Logan and T. Shenk (25) . For all plasmid constructions reported here, the simian virus 40 (SV40) large T antigen sequences were removed from the pMPCV2 plasmid by XhoI and BglII digestion and replaced by the appropriate HBV sequence. Restriction enzymes, DNA polymerases, T4 DNA ligase, and XhoI linkers were purchased from either Pharmacia (Piscataway, N.J.) or Boehringer Mannheim (Indianapolis, Ind.), and the digestions were performed as indicated by the manufacturers.
To generate recombinant adenoviruses by homologous recombination, 5 p.g of linearized plasmid and 5 ,ug of XbaI fragment of d1309 (3 to 100 map units [m.u.]) were cotransfected by the calcium phosphate and glycerol shock method, as described by Berkner and Sharp (3) (Fig. 1C) . Plaques which appeared 7 to 24 days later were picked and put into 2 ml of DMEM-2%FCS, and 1 ml of each stock was amplified on 293 cells in DMEM-2%FCS. After viral cytopathic effect was apparent, the media and cells were aspirated and stored at -80°C. The recombinant adenoviruses which contained the large envelope (HS1.HP), the middle envelope (HS2.HP), and the major envelope (HS.HP) sequences were identified by the following methods (Fig. 1D) Hirt (18) and Southern (50) . It should be noted that these recombinant adenoviruses lacked the El region and thus were dependent on an exogenous source of El proteins for replication. These functions are complemented by the 293 cell line (16, 25 by a modified method (48) . Several regions in the pre-S region were also sequenced by a modification of the Maxam and Gilbert method (27) . Concentration of secreted HBV envelope proteins. The medium (27 ml) was clarified at 10,000 rpm for 10 min, layered onto a 10 to 20% stepwise sucrose gradient (10 ml) in NTE buffer (130 mM NaCl, 10 mM Tris hydrochloride, pH 7.5, 1 mM EDTA) (17) , and centrifuged in a Beckman SW28 rotor at 25,000 rpm for 20 h. The pellet was suspended in NTE buffer and stored at 4°C.
Antisera. Anti-S serum was obtained from guinea pigs that had been inoculated with 40 mg of purified HBV surface antigen particles in complete Freund adjuvant on day 0, in incomplete Freund adjuvant on days 6 and 13, and in phosphate-buffered saline on day 35. Serum was collected 10 days after the fourth inoculation. This antiserum has strong reactivity to S determinants; however, we have not ruled out the possibility that it also reacts with pre-Sl and pre-S2 determinants. Rabbit anti-pre-S2 and rabbit anti-pre-Sl sera and monoclonal antibodies specific for pre-Sl and pre-S2 determinants were generously provided by A. R. Neurath (32) (11, 14) .
RESULTS
Sequence of adw2 isolate. To determine the similarity of the envelope gene of the HBV isolate used in this study with previously reported isolates (34, 59 ), we sequenced the pre-S and S regions. Comparison of the DNA sequence of the pre-S and S gene segments indicated that differences in the pre-S and S regions ranged from 2.0 to 2.25% and 0.6%, respectively (data not shown). However, most of these base changes did not result in alteration of the amino acid sequence. Variation of the encoded amino acids in the pre-S and S regions from the three isolates, as deduced from the DNA sequences, is shown in Table 1 . The differences in the amino acid sequence did not correspond to any of the amino acids which are thought to differentiate the w/r subtype determinants of the major envelope protein, amino acids 210, 273, 276, 289, and 323 (55) , or the d/y subtype determinants, amino acids 285 and 331 (33) . The pre-S2 protein sequence from amino acids 122 to 140 was also highly conserved between this adw isolate and two other adw isolates (33) . However, the amino acid in the 54th position of pre-S2, i.e., position 162 of this isolate, was alanine, in contrast to threonine found in other sequences of adw. Thus, this amino acid may not be required for the adw subtype, as suggested by others (24) . Of the six amino acid differences in the pre-Sl region of our isolate, five were shared by another adw sequence. Thus, the envelope gene of this HBV adw isolate appears to be very similar in amino acid sequence to previously described HBV adw isolates (34, 59) .
Expression of large, middle, and major envelope proteins. The three recombinant adenoviruses (Fig. 1D) were analyzed for the expression and secretion of envelope proteins by virally infected cells as measured by an RIA specific for the major envelope polypeptide. As shown in Fig. 2 Fig. 3A , HS.HP-infected 293 cells expressed two proteins, a 24,000-molecular-weight (24K) protein and a 27K protein, which were readily immunoprecipitated by guinea pig anti-S antiserum from the cell lysates, 4x-concentrated medium (Fig. 3A, lanes 1 and 4) , and medium (data not shown). These two proteins were similar in size to the major envelope proteins, p24 and gp27, isolated from HBV particles (14, 17) . The other proteins seen in these lanes were immunoprecipitated by preimmune guinea pig serum (lane 7). Rabbit antisera specific for the pre-S2 and pre-Sl regions (32) did not precipitate these two major envelope proteins (Fig. 3A , lanes 2 and 5 and 3 and 6, respectively).
Four HBV proteins (24K, 27K, 33K, and 36K) were detected in cell lysates (Fig. 3B, lane 1 anti-S serum. The 33K and 36K proteins (but not the 24K or 27K proteins) were precipitated by the rabbit anti-pre-S2 antiserum (Fig. 3B, lanes 2 and 5) . Because the 24K and 27K proteins were recognized by antisera to the S gene product but not by antisera specific for the pre-S2 amino acid sequence, they were probably major envelope proteins. As expected, none of the middle or major envelope proteins were immunoprecipitated by the rabbit anti-pre-Sl antiserum (Fig. 3B, lanes 3 and 6) . Densitometer tracings of the cell lysate (lane 1) and concentrated medium (lane 4) indicated that HS2.HP expressed and secreted ca. 80% middle envelope proteins (33K and 36K) and -20% major envelope proteins (24K and 27K).
HS1.HP-infected cells expressed six HBV proteins (24K, 27K, 33K, 36K, 39K, and 42K) in the cell lysates. The six HBV envelope proteins were not detected in either medium (Fig. 3C, lane 2 versus lane 4) or concentrated medium (data not shown). On a molar basis, the 39K and 42K proteins composed ca. 90% of the six HBV proteins immunoprecipitated by anti-S antiserum, the 24K and 27K proteins composed ca. 6%, and the 33K and 36K proteins composed ca. 4%, as calculated from densitometer tracings (Fig. 1C, lane  2) . Rabbit antisera specific for pre-S2 and pre-Sl immunoprecipitated the 39K and 42K proteins (data not shown; see Characterization of the middle and major envelope proteins. To determine whether the envelope proteins secreted by HS2.HP and HS.HP recombinant adenovirus-infected cells were assembled into surface antigen particles, the secreted proteins were analyzed by velocity sedimentation, CsCl isopycnic centrifugation, and electron microscopy. In the first approach, particulate materials in concentrated medium from HS2.HP-and HS.HP-infected cells were fractionated in a continuous sucrose gradient. As shown in Fig.  4A , envelope proteins from HS2.HP-and HS.HP-infected cells sedimented to a similar position in the sucrose gradient.
Portions of the two peak fractions from the sucrose gradients (Fig. 4A) were separately immunoprecipitated with anti-S and anti-pre-S2 antisera to determine the composition of the sedimentable material secreted by the HS2.HP-and HS.HP-infected cells. As shown in Fig. 4B , the peak of RIA-reactive material secreted by HS.HP-infected cells contained 24K and 27K proteins (lanes 1 to 4) . The peak of RIA-reactive material secreted by HS2.HP-infected cells contained predominantly 33K and 36K proteins as well as some 24K and 27K proteins (Fig. 4B, lanes 5, 6, 7, and 8 the medium from HS2.HP-and HS.HP-infected cells was 1.22 and 1.21 g/cm3, respectively, as determined by isopycnic CsCl gradient centrifugation (29a; data not shown). Examination of the peak gradient fractions by electron microscopy indicated that the medium of cells infected with either HS2.HP or HS.HP (Fig. 5 ) contained 22-nm particles, which were similar in size and density to surface antigen particles found in HBV-infected patients.
Inhibition of secretion of major and middle envelope proteins by expression of large envelope proteins. It has been shown that the large envelope proteins are constituents of both virions and surface antigen particles (17) . To investigate the interactions of the large envelope proteins with the middle or major envelope proteins during particle assembly, coinfection of 293 cells with a recombinant adenovirus containing the large envelope gene (HS1.SVP) and either HS2.HP or HS.HP at an MOI of 5 was performed. The cell lysates, medium, and concentrated medium were analyzed for the presence of the envelope polypeptides by immunoprecipitation and PAGE. Cells coinfected with HS.HP and HS1.SVP expressed the HBV proteins in the cell lysates as -60% major envelope, -4% middle envelope, and -36% large envelope proteins (Fig. 6A, lanes 1, 2, and 3 ). As shown in Fig. 6B (lanes 1, 2, and 3 ), cells coinfected with HS2.HP and HS1.SVP expressed -10% major envelope, -67% middle envelope, and -23% large envelope proteins in the cell lysates. Few or no envelope proteins were detected in the medium (data not shown) or concentrated medium of either set of coinfected cells (Fig. 6, lanes 4 to 6) by PAGE. To quantitate the effect of the presence of the large envelope proteins on the secretion of the major or middle envelope proteins, an RIA was used to measure the amount of envelope proteins in the medium of the cells infected individually with HS.HP, HS2.HP, or HS1.SVP and in the medium of cells coinfected with either HS1.SVP and HS.HP or HS1.SVP and HS2.HP (data not shown). The secretion of the HBV middle and major envelope proteins was inhibited more than 95% when the large envelope proteins constituted 20 to 40% of the expressed HBV proteins. DISCUSSION We used recombinant adenoviruses to express the major, middle, and large envelope proteins of HBV and to study their assembly. A summary of the relative concentrations of the major, middle, and large envelope proteins expressed by cells infected with the different recombinant adenoviruses is listed in Table 2 . The major envelope proteins expressed and secreted by HS.HP recombinant adenovirus-infected cells were assembled and secreted into the medium as 22-nm particles which had velocity sedimentation rates and buoyant densities (1.2 g/cm3) similar to those of the major envelope proteins expressed by numerous systems (reviewed in reference 56). These results confirmed previous reports (11, 36, 39, 40, 49) that the major envelope proteins by themselves can assemble into 22-nm particles, and thus the signals sufficient for assembly and secretion of surface antigen particles reside in the major envelope proteins themselves (39, 40, 56) .
Middle envelope proteins. The HS2.HP-infected cells expressed and secreted the middle envelope proteins (gp33 and gp36) and major envelope proteins (p24 and gp27) in a ca. 4:1 molar ratio. The secreted products were assembled into 22-nm particles with velocity sedimentation rates and buoyant densities similar to those of secreted major envelope proteins (Table 2) . One likely interpretation is that the particles secreted by HS2.HP-infected cells contain more middle envelope proteins on a molar basis than observed in native HBV surface antigen particles (17) . Cells infected with two different recombinant viruses also expressed and secreted middle envelope proteins and major envelope proteins in a higher molar ratio (1, 7) than observed in native HBV 22-nm particles (17) . Cells infected with a different recombinant adenovirus which contained the HBV middle envelope gene regulated by the El promoter also expressed and secreted middle and major envelope proteins, but the abundant HBV envelope proteins were the unglycosylated middle (31K) and major (24K) envelope proteins (1). Recently, Cheng et al. (7) observed that cells infected with vaccinia virus recombinants containing the middle envelope gene expressed, assembled, and secreted middle envelope proteins in 22-nm particles. Few or no major envelope proteins were detected in the cell lysates or medium of recombinant vaccinia virus-infected cells. In contrast to our results and those of others (1, 7) , the expression of the middle and major envelope proteins in a 3:1 molar ratio in Xenopus oocytes resulted in the inhibition of secretion of major envelope proteins (51) . However, the expression of 5 (22, 28, 40, 51) . Similar proportions are observed in native HBV particles (17 During HBV infection, assembled virions and HBV surface antigen particles were localized in the endoplasmic reticulum (ER) in HBV-infected liver tissue (13, 20, 21, 37) . In vitro studies have suggested that the major envelope proteins are initially synthesized as transmembrane proteins, are aggregated in the membrane of the ER, and bud into the lumen of the ER (12, 38) . Although glycosylation is not required for assembly or secretion of the spherical 22-nm particles (39) , comparison of the glycosylation pattern of the intracellular with the secreted major envelope protein gp27 suggested that the residence time of the assembled particles in the ER or early Golgi compartment is much longer than passage through the Golgi apparatus and the secretory process (39) . The results of analysis of the major envelope proteins expressed in the liver of transgenic mice (9) or in Xenopus oocytes (51) are consistent with this hypothesis. Although PAGE migration rates of the intracellular and the secreted gp27 expressed by HS.HP-infected cells were similar, the same proteins from HS2.HP-infected cells migrated at slightly different rates. Further studies are needed to determine whether these differences reflect variations in the residence time in the ER or Golgi compartment.
The large envelope proteins are found predominantly in the virions, with decreasing amounts present in the filamentous particles and spherical surface antigen particles (17) . HBV appears to have evolved regulatory mechanisms such as those proposed below for differential biosynthesis and assembly of the envelope proteins to ensure the efficient assembly and transport of the particles and virions during infection. First, regulation of transcription may be involved since abundant mRNA transcripts for the translation of middle and major envelope proteins have been detected in vivo and in vitro (6, 22, 35) , whereas mRNA arising from the promoter upstream of the pre-Sl region has been detected only in vitro (22, 35) . In vivo, the large envelope proteins could be translated from low levels of the latter mRNA (i.e., undetectable) or from the 3.8-kilobase mRNA which also serves as the template for reverse transcription (6) . Second, the data of Buscher et al. (5) imply that the various mRNA species from a virus related to HBV may have different levels of translational efficiency. Third, the large envelope proteins expressed in COS cells or Xenopus oocytes have been posttranslationally modified by the addition of myristic acid (42) , which may aid in anchoring the proteins in the ER. No myristic acid has been observed on the major and middle envelope proteins (42) . Fourth, interactions with other molecules such as the core proteins may also affect the rate of assembly of the envelope proteins.
Recombinant adenoviruses have been engineered to express the HBV envelope proteins as well as other foreign genes (11, 15) . The majority of 3-to 4-week-old hamsters inoculated with any of several adenovirus type 5 recombinants which express the major envelope proteins produced antibody to the HBV major envelope proteins (29a, 29b). Moss and colleagues have shown that several animal species inoculated with recombinant vaccinia viruses which express the major, middle, or large envelope proteins of HBV induced the production of antibody specific for HBV envelope determinants (7, 8, 30) . Thus, these data illustrate the feasibility of a recombinant adenovirus approach for an HBV vaccine or for other pathogenic agents.
